Thus, the ability to alter the nucleocytoplasmic interchange of essential cargo proteins like p53, p21WAF1/Cip1, cyclin B1/D1, and IκB by inhibiting XPO1 creates opportunities to target diverse pathways implicated in carcinogenesis, making XPO1 an attractive target for novel cancer therapies. This evidence concerns the gene XPO1 and cancer.